SG11201807080UA - Method and composition for treating cancer or skin lesion using a vaccine - Google Patents
Method and composition for treating cancer or skin lesion using a vaccineInfo
- Publication number
- SG11201807080UA SG11201807080UA SG11201807080UA SG11201807080UA SG11201807080UA SG 11201807080U A SG11201807080U A SG 11201807080UA SG 11201807080U A SG11201807080U A SG 11201807080UA SG 11201807080U A SG11201807080U A SG 11201807080UA SG 11201807080U A SG11201807080U A SG 11201807080UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- february
- pct
- vaccine
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Anesthesiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662300785P | 2016-02-27 | 2016-02-27 | |
| US201662328487P | 2016-04-27 | 2016-04-27 | |
| US201662338183P | 2016-05-18 | 2016-05-18 | |
| US201762444576P | 2017-01-10 | 2017-01-10 | |
| US201762455434P | 2017-02-06 | 2017-02-06 | |
| PCT/US2017/019433 WO2017147475A1 (en) | 2016-02-27 | 2017-02-24 | Method and composition for treating cancer or skin lesion using a vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807080UA true SG11201807080UA (en) | 2018-09-27 |
Family
ID=59686556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807080UA SG11201807080UA (en) | 2016-02-27 | 2017-02-24 | Method and composition for treating cancer or skin lesion using a vaccine |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3419661A4 (https=) |
| JP (3) | JP2019506435A (https=) |
| KR (1) | KR102873848B1 (https=) |
| CN (1) | CN108883168A (https=) |
| AU (1) | AU2017223970B2 (https=) |
| BR (1) | BR112018067550A2 (https=) |
| CA (1) | CA3015519A1 (https=) |
| CL (1) | CL2018002438A1 (https=) |
| CO (1) | CO2018009205A2 (https=) |
| HK (1) | HK1256935A1 (https=) |
| IL (1) | IL261340B2 (https=) |
| MX (1) | MX2018010338A (https=) |
| MY (1) | MY194694A (https=) |
| SG (1) | SG11201807080UA (https=) |
| WO (1) | WO2017147475A1 (https=) |
| ZA (1) | ZA201805679B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021013069A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人乳头瘤病毒11型l1蛋白 |
| PL4225351T1 (pl) * | 2020-10-12 | 2023-12-11 | Hpvvax, Llc | Kompozycja i sposób leczenia nowotworu z zastosowaniem szczepionki jako pierwszego składnika terapeutycznie czynnego w połączeniu z drugim składnikiem czynnym |
| WO2024097051A1 (en) * | 2022-10-31 | 2024-05-10 | Pyrojas Inc. | Immunotherapy compositions and methods of use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| GB0206359D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| EP3427755B1 (en) * | 2009-04-13 | 2020-10-21 | INSERM - Institut National de la Santé et de la Recherche Médicale | Hpv particles and uses thereof |
| CN101890160B (zh) * | 2009-04-28 | 2014-06-18 | 北京康乐卫士生物技术有限公司 | 多价重组人乳头瘤病毒疫苗及其应用 |
| SG177269A1 (en) * | 2009-06-25 | 2012-02-28 | Glaxosmithkline Biolog Sa | Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease |
| JP2014516075A (ja) * | 2011-06-06 | 2014-07-07 | シェブロン フィリップス ケミカル カンパニー エルピー | 癌治療のためのメタロセン化合物の使用 |
| US20130064849A1 (en) * | 2011-07-14 | 2013-03-14 | The Board Of Regents Of The University Of Texas | Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines |
| WO2013139744A1 (en) * | 2012-03-18 | 2013-09-26 | Glaxosmithkline Biologicals S.A. | Method of vaccination against human papillomavirus |
| US20130251782A1 (en) * | 2012-03-22 | 2013-09-26 | Leo Laboratories Limited | Topical application of ingenol mebutate with occlusion |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9974849B2 (en) * | 2013-10-13 | 2018-05-22 | Bioventures, Llc | Human Papilloma virus therapeutic vaccine |
| JP7037884B2 (ja) * | 2014-01-13 | 2022-03-17 | ベイラー リサーチ インスティテュート | Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン |
| CN107001430A (zh) * | 2014-10-24 | 2017-08-01 | 哈普威克斯有限责任公司 | 癌症和皮肤病变治疗 |
-
2017
- 2017-02-24 JP JP2018544832A patent/JP2019506435A/ja active Pending
- 2017-02-24 CN CN201780016785.3A patent/CN108883168A/zh active Pending
- 2017-02-24 KR KR1020187027123A patent/KR102873848B1/ko active Active
- 2017-02-24 MY MYPI2018001489A patent/MY194694A/en unknown
- 2017-02-24 CA CA3015519A patent/CA3015519A1/en active Pending
- 2017-02-24 EP EP17757336.7A patent/EP3419661A4/en active Pending
- 2017-02-24 BR BR112018067550-4A patent/BR112018067550A2/pt not_active Application Discontinuation
- 2017-02-24 WO PCT/US2017/019433 patent/WO2017147475A1/en not_active Ceased
- 2017-02-24 AU AU2017223970A patent/AU2017223970B2/en active Active
- 2017-02-24 HK HK18116062.9A patent/HK1256935A1/zh unknown
- 2017-02-24 SG SG11201807080UA patent/SG11201807080UA/en unknown
- 2017-02-24 MX MX2018010338A patent/MX2018010338A/es unknown
- 2017-02-24 CO CONC2018/0009205A patent/CO2018009205A2/es unknown
-
2018
- 2018-08-23 IL IL261340A patent/IL261340B2/en unknown
- 2018-08-24 ZA ZA201805679A patent/ZA201805679B/en unknown
- 2018-08-24 CL CL2018002438A patent/CL2018002438A1/es unknown
-
2021
- 2021-06-30 JP JP2021108667A patent/JP7732784B2/ja active Active
-
2023
- 2023-06-05 JP JP2023092142A patent/JP2023110038A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL261340B1 (en) | 2023-03-01 |
| EP3419661A4 (en) | 2019-10-23 |
| KR102873848B1 (ko) | 2025-10-17 |
| JP2023110038A (ja) | 2023-08-08 |
| BR112018067550A2 (pt) | 2019-10-01 |
| AU2017223970B2 (en) | 2022-01-27 |
| EP3419661A1 (en) | 2019-01-02 |
| JP2019506435A (ja) | 2019-03-07 |
| CO2018009205A2 (es) | 2018-09-20 |
| MY194694A (en) | 2022-12-15 |
| JP2021155448A (ja) | 2021-10-07 |
| MX2018010338A (es) | 2018-11-09 |
| HK1256935A1 (zh) | 2019-10-04 |
| ZA201805679B (en) | 2019-11-27 |
| AU2017223970A1 (en) | 2018-09-13 |
| WO2017147475A1 (en) | 2017-08-31 |
| CL2018002438A1 (es) | 2019-01-04 |
| JP7732784B2 (ja) | 2025-09-02 |
| KR20180112043A (ko) | 2018-10-11 |
| CA3015519A1 (en) | 2017-08-31 |
| CN108883168A (zh) | 2018-11-23 |
| IL261340A (en) | 2018-11-29 |
| IL261340B2 (en) | 2023-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201900028VA (en) | Crispr/cas9-based compositions and methods for treating cancer | |
| SG11201807965YA (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| SG11201906543RA (en) | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201805229YA (en) | Means and methods for treating hbv | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201901501UA (en) | Compositions and methods for enhancing cancer radiotherapy | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
| SG11201810454YA (en) | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201907207UA (en) | Pharmaceutical combinations comprising an anti-ly75 antibody | |
| SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| SG11201810793XA (en) | Pharmaceutical combinations | |
| SG11201811482YA (en) | Double targeted constructs to affect tumor kill | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201811763SA (en) | B-cell-mimetic cells |